A 59-year-old womanwith chronic active hepatitis C was treated with recombinant human interferon alpha-2a. After three days of administration, the patient complained of diplopia with dizziness and head heaviness. Ophthalmic examinations revealed a disturbance of the movement of left eye ball to the outer side without any other neurological signs. The diplopia, which was diagnosed as abducent nerve paralysis, improved rapidly and reversed at about 6 weeks after discontinuation of interferon and during infusion of hydrocortisone. To our knowledge, this is the first report of abducent nerve paralysis associated with alpha-2a interferon. (Internal Medicine 33: 637-640, 1994) 
Introduction
Neurological side effects during interferon therapy have been reported by several authors in recent years (1) (2) (3) (4) (5) (6) (7) . The predominant neurological signs are encephalopathy with marked somnolence, lethargy, convulsion and confusion (2, 3) , and mild peripheral nerve disturbances are seen such as numbness or tingling (8) . Here, we describe a patient with chronic active hepatitis C, in which abducent nerve paralysis was attributed to treatment with recombinant alpha-2a interferon. Ocular symptoms are rare signs amongmanyother side effects following administration of interferon, but when it occurs, the patient greatly suffers. As there is little information on the treatment and prognosis of this oculopathy, this case is presented with literature data.
Case Report
Wereport a 59-year-old womanwith hepatic disturbance and hypertension since she was 48 years old. She consulted us with the complaint of general fatigue in July 1992 and was revealed to have moderate liver dysfunction (AST 108 U/L and ALT 104 U/L), and positivity for hepatitis C virus (HCV) antibody and HCV-RNA in her serum examinations. Subtype of HCVwas type II. In her medical history, she had no blood transfusion nor operation.
The patient was admitted to the Hepatology Department of Shimonoseki National Hospital for further examination and treatment of her liver disease. Physical examination revealed hepatomegaly.
Blood chemistry on admission showed hypoproteinemia, moderate elev ation of trans aminase and biliary enzymes, but normal in indocyanine green retention test (Table  1) . Serum blood sugar level was slightly elevated, but it was controllable by diet therapy only through hospitalization.
Ophthalmoscopic examination before treatment was normal. Laparoscopy disclosed an enlarged liver with diffused small depressions and proliferation of small vessels on the surface of the liver (Fig. 1) . The diagnosis of chronic active hepatitis was confirmed by liver biopsy (Fig. 2) , and administration of recombinant humanalpha-2a interferon was started at a dose of 9xlO6 units daily. However, three days after the treatment, the patient suddenly complained of diplopia accompanied by dizziness, head heaviness and unsteadiness on her feet. Ophthalmic examinations revealed difficulty in moving the left eye ball to the outer side. The pupillary light reflexes were reserved, the size of both pupils were normal, no ptosis of the eyelid was observed and the optic disks were normal. The diplopia worsened whenshe looked at her left side. No other neurological or psychiatric signs were detected such as convulsion, confusion or unconsciousness.
A computed tomography (CT) scan of the brain showed normal ventricles and sulci, and no enhancementoccurred after injection of contrast medium (Fig. 3 ). According to these findings, the diagnosis of mononeural left side abducent nerve paralysis was made. The interferon administration was stopped after 3 days of treatment. Drip infusions of hydrocortisone (100 mg/day) and vitamin Bl 6 l2 were started. Clinical evolution was favorable after discontinuation of interferon and these regimens. At first the dizziness and unsteadiness, and the diplopia gradually improved about 2 weeks after the onset (Fig. 4) . Her double vision disappeared 4 weeks later. Hepatic dysfunction temporarily become worse after the cessation of interferon, but recovered by intravenous administration ofglyczrrhizin (Strong neo-minophagen C 2A). The ocular situation has now remained normal.
Discussion
Chronic liver disease associated with hepatitis C virus (HCV) is a growing health problem. This is mainly chronic active hepatitis (CAH), the precursor of liver cirrhosis which has a high risk for hepatocellular carcinoma. The number of patients with HCVinfection in Japan is about 1.5% of the population. The use of biologic response modifiers and immunotherapyis a newer approach to the treatment of viral hepatitis B and C (9). Alpha-interferon, which is in a family of biological mediators, is now available as an anti-viral agent or immunomodifier. As beneficial effects have been reported for patients with chronic active hepatitis C, the introduction of interferon therapy is rapidly increasing. According to the extent of dose and frequency of interferon administration, the occurrence of side effects becomesa major problem in this therapy. Side effects are divided in two groups. The first group occurs consistently, symptoms such as an influenza-like illness; the other group is less commonbut is found as a critical disease which appears in any organ of the body; are constitutional, hepatic, gastrointestinal, cardiovascular and neurologic manifestations. Adverseneurological reaction is variegated, including paresthesia, fatigue, somnolence, lethargy, depression, conceptual disorganization, neurological deficits, mental deterioration and others (1) (2) (3) (4) (5) (6) (7) (8) . These side effects of mild to markedly severe are reported to develop at a rate of 3 to 9%in Japan (3), but about 17% in European countries (10) . On the other hand, neuropathy which is caused by the hemorrhage of cerebrovascular accident attributes to thrombocytopeniaafter a large amountof interferon administration (1 1). Amongthe neurological side effects during interferon therapy, most cases originate in the central nerve system, and in a few patients peripheral nerve neuropathy is observed (8, (12) (13) (14) (15) . A patient with neurologic amyotrophy was also described recently (8, 13, 14) . The patient reported here had an episode of abducent nerve paralysis during the therapy with recombinant alpha-2a interferon and no other neuropathy accompanied. The etiology of the ophthalmophlegiais considered as trauma, aneurysmof cerebral artery, tumor growth, infections, diabetes mellitus , and retinal bleeding. But, various tests excluded expansive foci at the base of brain, acute and chronic infections, diabetic neuritis or retinopathy for ocular fundi. The clinical course of the events, the absence of any other cause, and the reversibility of this paralysis after cessation of interferon suggest that the ocular problem was induced by alpha-2a interferon. Although the ophthalmic side effects due to interferon was rarely seen, when it occurred, the patient became very anxious and was distressed. As far as we know, there is no description of abducent nerve paralysis during interferon alpha-2a treatment.
Of the other reports concerning oculopathy induced by interferon, a case of bilateral oculomotor nerve paralysis in a patient with hairly-cell leukemia has been presented ( 1 6). After interferon was withdrawn, the neurological abnormalities disappeared. Another patient with ptosis of the left eyelid and intermittent diplopia after application of interferon wasalso reported (17). These symptoms subsided after therapy was stopped, but ptosis and diplopia recurred when interferon was resumed. Loss of sight due to bilateral lesions in the occipital lobes was a severe side effect produced by interferon (18). It is termed as cortical blindness and accompanied by high fever, weakness and lethargy. The neurological manifestations were not reversible and the patient died. In the literature, many ophthalmic side effects due to interferon were improved after discontinuation, but in a few cases they were irreversible and the prognosis was poor. The mechanism underlying interferon-induced oculopathy is obscure but mayinvolve the direct toxic effect of this agent on the central or peripheral nervous system (18-23). Some possible hypotheses were postulated. This neurotoxic reaction maybe attributable in part to the effect of alpha-interferon on endorphin function. Intracerebral injection of alpha-interferon in animals caused endorphin-like opioid effects and produced neurological symptoms, suggesting that alpha-interferon could bind to opiate receptors (22). Anevidence that interferon had opiate-like activity was also provided (24). Moreover, alphainterferon is suspected to have an immunologic cross-reactivity with peptides such as cortico-tropin and endorphin, and alters nerve cells (25). Cytokines, such as interleukin-1 and tumor necrosis factor, which are induced by interferon may interfere with cell regulatory mechanisms (26). At the moment, we cannot exclude the possibility that one or both of these hypotheses are responsible for these clinical features. However, in consideration of interferon therapy it should be noted that receptors for interferons have been found in manytypes of cells in man (23), particularly in the nervous system.
